Get the Stockscreener App
47.69
0.02%
-0.01
After Hours:
47.69
Tourmaline Bio Inc stock is traded at $47.69, with a volume of 1.57M.
It is down -0.02% in the last 24 hours and up +115.11% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$47.70
Open:
$47.71
24h Volume:
1.57M
Relative Volume:
2.28
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
82.44
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+0.19%
1M Performance:
+115.11%
6M Performance:
+175.19%
1Y Performance:
+127.10%
1-Day Range:
$47.67
$47.77
1-Week Range:
$47.59
$47.77
52-Week Range:
$11.56
$47.77
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
47.69 | 1.23B | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML) - Eastern Progress
26,000 Shares in Tourmaline Bio, Inc. $TRML Purchased by Wesbanco Bank Inc. - MarketBeat
Fed Meeting: What is the next catalyst for Tourmaline Bio IncInsider Buying & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Quarterly Earnings: Is Tourmaline Bio Inc. stock a good dividend stockGold Moves & Free Expert Verified Stock Movement Alerts - خودرو بانک
RSI Check: Does Tourmaline Bio Inc stock have upside surprise potentialJuly 2025 Levels & Real-Time Volume Spike Alerts - خودرو بانک
Tourmaline Bio (NASDAQ:TRML) Reaches New 12-Month HighHere's Why - MarketBeat
Big Picture: Is Tourmaline Bio Inc. gaining market shareJuly 2025 Spike Watch & Risk Controlled Swing Trade Alerts - خودرو بانک
Market Pulse: What are AA Mission Acquisition Corps technical support levelsSell Signal & Daily Profit Maximizing Trade Tips - خودرو بانک
Tourmaline Bio (NASDAQ:TRML) Downgraded by BMO Capital Markets to Market Perform - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Cut to Neutral at Chardan Capital - MarketBeat
Guggenheim Reaffirms "Neutral" Rating for Tourmaline Bio (NASDAQ:TRML) - MarketBeat
Setup Watch: Whats Tourmaline Bio Incs historical returnWeekly Trade Summary & Weekly Sector Rotation Insights - خودرو بانک
Institution Moves: Is Tourmaline Bio Inc a cyclical or defensive stockWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - خودرو بانک
Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition - ca.finance.yahoo.com
BMO Capital Downgrades Tourmaline Bio to Market Perform From Outperform, Raises Price Target to $48 From $35 - MarketScreener
This New Mountain Finance Analyst Turns Bearish; Here Are Top 3 Downgrades For Monday - Benzinga
BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news - Investing.com Canada
905,000 Shares in Tourmaline Bio, Inc. $TRML Acquired by Octagon Capital Advisors LP - MarketBeat
Novartis to Buy US Biotech Tourmaline Bio for $1.4 Billion - MSN
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpShould You Buy? - MarketBeat
Tourmaline Bio (TRML): Assessing Valuation as Market Interest Grows - uk.finance.yahoo.com
Tourmaline Bio (NASDAQ:TRML) Cut to "Neutral" at Wedbush - MarketBeat
Tourmaline Bio Updates Executive Severance Plan - MSN
Tourmaline Bio (NASDAQ:TRML) Lowered to "Hold" Rating by Piper Sandler - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week HighWhat's Next? - MarketBeat
Tourmaline Bio stock hits 52-week high at 47.69 USD - Investing.com India
Why Tourmaline Bio Inc. stock could outperform in 20252025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Tourmaline Bio stock hits 52-week high at 47.69 USD By Investing.com - Investing.com Australia
Tourmaline Bio (NASDAQ:TRML) Sees Strong Trading VolumeHere's What Happened - MarketBeat
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline - MSN
Tourmaline Bio (NASDAQ:TRML) Stock Rating Lowered by Truist Financial - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Lowered to "Neutral" Rating by HC Wainwright - MarketBeat
Tourmaline Bio, Inc. $TRML Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
American Century Companies Inc. Raises Stake in Tourmaline Bio, Inc. $TRML - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Hold" by Brokerages - MarketBeat
Novartis to Buy Tourmaline Bio for $48 Per Share in Cash - MSN
Lifesci Capital Downgrades Tourmaline Bio (NASDAQ:TRML) to Hold - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Cut to "Hold" at Jefferies Financial Group - MarketBeat
Novartis adds late-stage anti-inflammatory asset with $1.4 billion Tourmaline Bio acquisition - DOTmed
Biotech Stocks To ConsiderSeptember 9th - MarketBeat
Tourmaline Bio Merges with Novartis for $1.4 Billion - MSN
Hsbc Holdings PLC Acquires Shares of 10,357 Tourmaline Bio, Inc. $TRML - MarketBeat
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - FinancialContent
Piper Sandler Downgrades Tourmaline Bio to Neutral From Overweight, Lowers Price Target to $48 From $65 - MarketScreener
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Novartis Acquires Tourmaline Bio for $1.4 Billion | - openPR.com
Novartis Acquires Tourmaline Bio for $1.4 Billion | DelveInsight’s Perspective on ASCVD Market Impact, Competitive Landscape and Anti-Inflammatory Pipeline Expansion - Barchart.com
Best Medical Stocks Worth WatchingSeptember 9th - MarketBeat
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):